Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2015 / N 3

Применение новых оральных антикоагулянтов в профилактике кардиоэмболического инсульта у пациентов с фибрилляцией предсердий: от рекомендаций к реальной практике (библиография)
Л.В. Стаховская, К.С. Мешкова, В.В. Гудкова

1. Линчак Р.М., Комков Д.С., Недбайкин А.М. и др. Какие антитромботические препараты предпочитают российские врачи для профилактики инсульта и системных эмболий у больных с фибрилляцией предсердий. Материала Российского национального конгресса кардиологов. Москва, 2015. Стр. 400–401.
2. Национальные рекомендации по диагностике и лечению фибрилляции предсердий, 2012 // http://scardio.ru/rekomendacii/rekomendacii_rko/nacionalnye_rekomendacii_po_diagnostike_i_lecheniyu_fibrillyacii_predserdiy_2012/
3. Сучкова С.А., Андреев Д.А., Салпагарова З.К. и др. Регистр по применению новых оральных антикоагулянтов при тромбозе левого предсердия у пациентов с “неклапанной” фибрилляцией/трепетанием предсердий. Материал Российского национального конгресса кардиологов. Москва, 2015.
4. Banerjee A., Lane D.A., Torp-Pedersen C., Lip G.Y. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) vs. no treatment in a “real world” atrial fibrillation population: a modeling analysis based on a nationwide cohort study // Thromb Haemost. 2012. V. 107. P. 584–589.
5. Broukhim M., Halperin J.L. Stroke prevention in the high-risk atrial fibrillation patient: medical management // Curr. Cardiol. Rep. 2011. V. 13. P. 9–17.
6. Camm A.J., Lip G.Y., De Caterina R. et al.; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association // Eur. Heart J. 2012. V. 33. № 21. P. 2719–2747.
7. Granger C.B., Alexander J.H., McMurray J.J. et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation // N. Engl. J. Med. 2011. V. 365. P. 981–992.
8. Connolly S.J., Ezekowitz M.D., Yusuf S. et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation // N. Engl. J. Med. 2009. V. 361. P. 1139–1151.
9. Connolly S.J., Ezekowitz M.D., Yusuf S. et al.; Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial // N. Engl. J. Med. 2010. V. 363. P. 1875–1876.
10. Connoly S.J., Walentin L., Ezekowitz M.D. et al. The long-term multicenter observation study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study // Circulation. 2013. V. 128. P. 237–243.
11. European Medicines Agency updates on safety of Pradaxa // http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/11/WC500117818.pdf
12. Friberg L., Rosenqvist M., Lip G.Y. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation Cohort study // Eur. Heart J. 2012. V. 33. P. 1500–1510.
13. Gallagher A.M., Rietbrock S., Plumb J., van Staa T.P. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? // J. Thromb. Haemost. 2008. V. 6. P. 1500–1506.
14. GLORIA-AF Registry Program – Second and Third Phases https://clinicaltrials.gov/ct2/show/NCT01468701
15. Palareti G., Salomone L., Cavazza M. et al. Stroke/Thromboembolism and Intracranial Hemorrhage in a Real-world Atrial Fibrillation Population: The Complications of Atrial Fibrillation in the Bologna Area (CAFBO) Study // Chest. 2014. V. 146. P. 1073–1080.
16. Gupta M., Singh N., Cox J.L. et al. High rates of concomitant antiplatelet use in patients with atrial fibrillation treated with oral anticoagulation: Insights from the Stroke Prevention and Rhythm Intervention in Atrial Fibrillation (SPRINT-AF) registry. American Heart Association 2014 Scientific Sessions; Chicago, 2014. // Canad. J. Cardiol. 2014. V. 30. P. S183.
17. Hart R.G., Pearce L.A., Aguilar M.I. et al. Metaanalysis: antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation // Ann. Intern. Med. 2007. V. 146. P. 857–867.
18. Healey J., Oldgren J., Parekh A. et al. Global variations in the 1-year rates of death and stroke in 15,432 patients presenting to the emergency department with atrial fibrillation in 47 countries. Munich: The RE-LY AF Registry, 2012.
19. Holbrook A.M., Pereira J.A., Labiris R. et al. Systematic overview of warfarin and its drug and food interactions // Arch. Intern. Med. 2005. V. 165. P. 1095–1006.
20. Iung B., Baron G., Butchart E.G. et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease // Eur. Heart J. 2003. V. 24. P. 1231–1243.
21. January C.T., Wann L.S., Alpert J.S. et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation // J. Am. Coll. Cardiol. 2014. V. 64. P. 1–76.
22. Kernan W.N., Ovbiagele B., Black H.R. et al.; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association // Stroke. 2014. V. 45. P. 2160–2236.
23. Kirchhof P., Ammentorp B., Darius H. et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events--European Registry in Atrial Fibrillation (PREFER in AF) // Europace. 2014. V. 16. P. 6–14.
24. Larsen T.B., Gorst-Rasmussen A., Rasmussen L.H. et al. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation // Am. J. Med. 2014. V. 127. P. 650–656.
25. Le Heuzey J.Y., Breithardt G., Camm J. et al. The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation // Am. J. Cardiol. 2010. V. 105. P. 687–693.
26. Lip G.Y., Laroche C., Dan G.A. et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry // Europace. 2014. V. 16. P. 308–319.
27. Lip G.Y., Nieuwlaat R., Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation // Chest. 2010. V. 137. P. 263–272.
28. Mant J., Hobbs R., Fletcher K. et al.; BAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fi brillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial // Lancet. 2007. V. 370. P. 493–503.
29. Patel M.R., Mahaffey K.W., Garg J. et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation // N. Engl. J. Med. 2011. V. 365. P. 883–891.
30. Piccini J.P., Holmes D.N., Ollis D.M. et al. Patterns of atrial fibrillation and treatment strategies vary according to provider specialty across community practice settings: findings from the ORBIT-AF Registry // Circulation. 2011. V. 124. P. A16415.
31. PistersR. , Lane D.A., Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleedingin patients with atrial fibrillation: The Euro Heart Survey // Chest. 2010. V. 138. P. 1093–1100.
32. Ruff C.T., Giugliano R.P., Braunwald E. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials // Lancet. 2013. V. 383. P. 955–962.
33. Chatterjee S., Sardar P., Biondi-Zoccai G., Kumbhani D.J. New oral anticoagulants and the risk of intracranial hemorrhagetraditional and bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation // JAMA Neurol. 2013. V. 70. P. 1486–1490.
34. Sorensen R., Gislason G., Torp-Pedersen C. et al. Dabigatran use in Danish atrial fibrillation patients in 2001: a nationwide study // BMJ. Open 2013. V. 3. P. e002758.
35. StegG., Bhatt D.L., Wilson P.W.F. et al. One–year cardiovascular event rates in outpatients with atherothrombosis // JAMA 2007. V. 297. P. 1197–1206.
36.Turakhia M., Solomon M.D., Jhaveri M. et al. Burden, timing, and relationship of cardiovascular hospitalization to mortality among Medicare beneficiaries with newly diagnosed atrial fibrillation // Am. Heart J. 2013. V. 166. P. 573–580.
37. Wouters H, Thijs V, Annemans L. Costeffectiveness of dabigatranetexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium // J. Med. Econ. 2013. V. 16. P. 407–414.
38. Wurster M.W. Dabigatran use in the real world: Preliminary results of a prospective trial comparing outcomes with dabigatran and warfarin therapy. Proceedings of the Thrombosis and Hemostasis summit of North America: Research abstracts // Am. J. Hematol. 2012. V. 87. P. S146–S200.
  

[ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]